Conspiracy of Silence: How the FDA Allows Drug Companies to Abuse the Accelerated Approval Process. Staff Summary of Responses by the Food and Drug Administration and the Securities and Exchange Commission to Correspondence From Rep. Edward J. Markey (D-MA), Senior Member, Energy and Commerce Committee, U.S. House of Representatives
Washington, DC: Energy and Commerce Committee, 2005 June; 26 p.
Showing items related by title, author, creator and subject.
Mutual Recognition Agreement: Food and Drug Administration's Progress in Assessing Equivalency of European Union Pharmaceutical Inspection Programs Letter From William J. Scanlon, Director, Health Financing and Public Health Issues to Rep. Thomas Bliley, Jr. and Rep. John D. Dingell on the U.S. Congress, House, Committee on Commerce and Rep. Fred Upton and Rep. Ron Klink on the U.S. Congress, House, Committee on Commerce, Subcommittee on Oversight and Investigations Scanlon, William J. (United States. General Accounting Office [GAO]. Health, Education and Human Services Division, 1999-02-26)
The Drug Approval Process at the Food and Drug Administration: New Biotechnology as a Paradigm of a Science-Based Activist Approach Miller, Henry I., and Young, Frank E. (1989-03)